February 24, 2015

An American Academy of Neurology study found that people who exhibit a resistance to aspirin may be more likely to have more severe strokes. 

February 20, 2015

Actavis on Friday gained approval for a generic version of Reckitt Benckiser's Subutex, indicated for the treatment of opioid dependence.

February 12, 2015

Sandoz on Thursday launched telmisartan tablets, the generic version of Micardis from Boehringer Ingelheim. The drug is used to treat hypertension, the company said.

 

February 9, 2015

Mylan Inc. and its subsidiary Mylan Pharmaceuticals are being sued by Bayer Healthcare, Bayer Healthcare Pharmaceuticals and Onyx Pharamceuticals in relation to the filing of an abbreviated new drug application for sorafenib tablets, the generic version of Nexavar. 

 

February 5, 2015

Merck earlier this week announced that Belsomra (suvorexant) is now available at pharmacies in the United States for the treatment of insomnia.

February 3, 2015

Teva Pharmaceuticals on Tuesday announced the introduction of dexmethylphenidate hydrochloride extended-release capsules, CII, in 10-mg dosage strength.

February 3, 2015

Zogenix last week announced that the Food and Drug Administration approved a new formulation of the company's Zohydro ER (hydrocodone bitartrate) extended-release capsules, CII.

January 30, 2015

Janssen Therapeutics on Thursday announced that the Food and Drug Administration has approved its Prezcobix (darunavir 800 mg/cobicistat 150 mg) tablets. The drug is used to treat human immunodeficiency virus in combination with other antiretovirals for treatment-naïve and treatment-experienced adults with no darunavir resistance-associated substitutions, according to the company.

 

January 27, 2015

Symplmed Pharmaceuticals announced that the Food and Drug Administration approved Prestalia (perindopril arginine and amlodipine) tablets to treat hypertension. 

January 26, 2015

Purdue Pharma on Monday announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets CII. According to the company, the once-daily drug is the first and only hydocodone product to be recognized by the Food and Drug Administration as having properties that deter misuse and abuse via chewing, snorting and injection.

January 22, 2015

Camber Pharmaceuticals on Thursday announced the launch of pantoprazole sodium delayed-release tablets USP, the generic version of Pfizer's Protonix. The drug is used to treat gastro esophageal reflux disease and damage to the esophagus.

 

January 15, 2015

Mylan on Thursday announced the launch of lamivudine tablets, 100 mg, the generic version of Epivir-HBV from GlaxoSmithKline. 

January 14, 2015

Egalet Corp. last week announced the licensing and acquisition of two pain products. Egalet has agreed to license worldwide rights to Oxaydo (oxycodone HCI, USP) tablets for oral use only -CII, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting from Acura Pharmaceuticals, the company stated.

January 13, 2015

Prasco Labs., Takeda Pharmacuetical Company Limited and Takeda's wholly owned subsidiary Takeda Pharmaceuticals U.S.A. on Tuesday announced that Prasco and TPUSA entered into a distribution and supply agreement for the rights to distribute colchicine tablets, USP, the authorized generic of Colcrys tablets. 

 

January 12, 2015

Perrigo on Monday announced that it has launched clobetasol propionate spray, 0.05%, the generic equivalent to Clobex spray, 0.05%. 

January 9, 2015

Camber Pharmaceuticals on Friday announced the launch of zolmitriptan tablets in 2.5- and 5-mg dosage strengths.

January 8, 2015

Camber Pharmaceuticals on Thursday announced the launch of valsartan tablets USP in 40-, 80-, 106- and 320-mg dosage strengths.

 

January 7, 2015

Lupin Pharmaceuticals on Tuesday launched its valsartan tablets USP in 40-, 80-, 160- and 320-mg dosage strengths. The drug is the generic version Novartis's Diovan tablets.

January 7, 2015

Teva Pharmaceutical on Tuesday announced the Food and Drug Administration approved the launch of the company's valsartan tablets, the generic version of Diovan tablets from Novartis. 

 

January 6, 2015

Aurobindo Pharma on Tuesday announced that the company has received final approval from the U.S. Food & Drug Administration to manufacture and market Valsartan Tablets.

January 5, 2015

Mylan announced the introduction of valsartan tablets USP in 40-, 80-, 160- and 320-mg dosage strengths. 

December 22, 2014

The Food and Drug Administration granted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as detected by an FDA-approved test.

December 18, 2014

Dr. Reddy’s Laboratories announced Tuesday that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of the antiviral Valcyte (Valganciclovir) tablets, in the U.S. market.

December 16, 2014

Dr. Reddy's Labs announced the launch of valganciclovir tablets USP in 450-mg strength.